No CrossRef data available.
Article contents
Cyproheptadine effect on combat related PTSD nightmares
Published online by Cambridge University Press: 16 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:
Recent studies have shown the role of sorotonergic system in posttraumatic stress disorder. Terazodone and Nefazodone, (5HT2 antagonist) ameliorated PTSD nightmares but the reports are mixed. This study prompted an open trial of cyprohepatadine for Iran versus Iraq combat PTSD patient nightmares.
Methods:
25 patients studied in an eight - week, Before - After trial of cyproheptadine, the participants were male and chronic PTSD patients with combat related nightmare the exclusion criteria in clouded current substance abuse or dependence, psychotic disorder and any medical condition that contraindicated the use of cyproheptadine.
Results:
Five patients were excluded from the study because of side effects including dizziness and somnolence. Twenty patients completed the study. Average of nightmare severity decreased from 6.85 to 5.05, which was statistically significant (P<0.01).
Discussion:
Cyproheptadine, 5HT2 antagonist may be effective in PTSD nightmare treatment.
- Type
- Poster Session 2: Anxiety, Stress Related, Impulse and Somatoform Disorders
- Information
- European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S266
- Copyright
- Copyright © European Psychiatric Association 2007
You have
Access
Comments
No Comments have been published for this article.